OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacogenomics Journal is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study	59
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data	41
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States	29
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform	25
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors	23
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study	22
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study	22
STRIPE partners in precision medicine series: provider perspective	21
Using ChatGPT to predict the future of personalized medicine	21
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population	17
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care	17
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients	16
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle	15
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder	15
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing	13
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration	13
Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients	12
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?	12
AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients	11
TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer	11
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis	11
APF2: an improved ensemble method for pharmacogenomic variant effect prediction	11
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress	11
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance	10
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population	10

Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications	8
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects	7
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci	7
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)	7
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder	7
A blockchain-based framework to support pharmacogenetic data sharing	7
Genetic markers of early response to lurasidone in acute schizophrenia	7
Polymorphisms at CYP enzymes, NR1I2 and NR1I3 in association with virologic response to antiretroviral therapy in Brazilian HIV-positive individuals	7
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study	7
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients	6
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer	6
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics	6
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review	6